

# 83 - References

## References

### Schizophrenia and related psychoses CHAPTER 1 References

1. Shirley M, et al. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. *Drugs* 2014; 74:1097–1110.
2. US Food and Drug Administration. Highlights of Prescribing Information. Abilify Maintena (aripiprazole) for extended-release suspension for intramuscular use. 2020 (last accessed August 2024); [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/202971s013lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202971s013lbl.pdf).
3. Raoufinia A, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. *Curr Med Res Opin* 2015; 31:583–592.
4. Otsuka Pharmaceuticals (UK) Ltd. Summary of Product Characteristics. Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection. 2024 (last accessed October 2024); <https://www.medicines.org.uk/emc/product/7965/smpc>.
5. Raoufinia A, et al. Aripiprazole once-monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. *Int J Neuropsychopharmacol* 2017; 20:295–304.
6. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel- arm, multiple-dose study. *Schizophr Res* 2013; 150:281–288.
7. Otsuka Pharmaceutical Co Ltd. Highlights of Prescribing Information. ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension, for intramuscular use. 2017 (last accessed October 2024); [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/202971s013lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202971s013lbl.pdf).
8. Otsuka Pharmaceuticals (UK) Ltd. Summary of Product Characteristics. Abilify Maintena 960 mg prolonged-release suspension for injection in pre-filled syringe. 2024 (last accessed October 2024); <https://www.medicines.org.uk/emc/product/15679/smpc>.
9. Otsuka Pharmaceutical Co Ltd. Highlights of Prescribing Information. ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension for intramuscular use. 2023 (last accessed October 2024); [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/217006s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217006s000lbl.pdf).
10. Citrome L, et al. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with schizophrenia in a randomized, open-label, parallel-arm, pivotal study. *J Clin Psychiatry* 2023; 84:23m14873.
11. Harlin M, et al. A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting

- injectable in adults with schizophrenia or bipolar I disorder. *CNS Drugs* 2023; 37:337–350.
12. McIntyre RS, et al. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study. *Curr Med Res Opin* 2023; 39:1021–1030.
  13. Samalin L, et al. Evaluating the efficacy and safety of the currently available once-every--two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults. *Expert Rev Neurother* 2024; 24:291–298.
  14. Alkermes Inc. ARISTADA INITIO™ (aripiprazole lauroxil) extended-release injectable suspension [product monograph]. 2020 (last accessed October 2024); <https://www.aristadacaresupport.com/downloadables/ARISTADA-INITIO-ARISTADA-Payer--Hospital-Monograph.pdf>.
  15. Hard ML, et al. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. *J Clin Psychopharmacol* 2017; 37:289–295.
  16. Turncliff R, et al. Relative bioavailability and safety of aripiprazole lauroxil, a novel once--monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. *Schizophr Res* 2014; 159:404–410.
  17. Alkermes Inc. Highlights of Prescribing Information. ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for intramuscular use. 2018 (last accessed October 2024); [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/207533s013lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207533s013lbl.pdf).
  18. Citrome L, et al. Safety and tolerability of starting aripiprazole lauroxil with aripiprazole lauroxil nanocrystal dispersion in 1 day followed by aripiprazole lauroxil every 2 months using paliperidone palmitate monthly as an active control in patients with schizophrenia: a post hoc analysis of a randomized controlled trial. *J Clin Psychiatry* 2024; 85:23m15095.
  19. Harlin M, et al. Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison. *Neuropsychiatr Dis Treat* 2023; 19:1409–1416.

---

Revision #1

Created 2026-01-04 20:13:58 UTC by Omar Ayman

Updated 2026-01-04 20:13:58 UTC by Omar Ayman